Michelle Mone: The Tory peer facing ‘shocking’ allegations of pandemic profiteering
The former lingerie entrepreneur reportedly made £29m in profit from dubious PPE firm she recommended to government ministers

If you’re like me, and your eyes glaze over at the words “PPE” and “Covid contracts”, then you may not have taken in the truly “shocking” details of how the Tory peer Michelle Mone allegedly made millions from the pandemic, said Camilla Long in The Sunday Times.
In May 2020, the former lingerie entrepreneur emailed Michael Gove and others telling them that “my team in Hong Kong” could help the Government secure desperately needed protective equipment for healthcare workers, and proposing a firm called PPE Medpro as a “VIP fast track” supplier. The company didn’t even exist as a legal entity until five days after that, and it had no assets or special expertise other than contacts at a factory in China. Yet within weeks, this start-up was miraculously awarded £203m worth of contracts to supply PPE, about half of which proved to be defective and was not used.
The wastefulness is appalling, but it is the sheer shadiness of the deal that is really sickening, said Barbara Davies in the Daily Mail. Mone and her husband, Doug Barrowman, claimed to have no involvement with PPE Medpro. Yet the firm’s registered owner was an employee at his Isle of Man company; and leaked HSBC reports, seen by The Guardian and the FT, appear to show that he was paid £65m in PPE Medpro’s profits; and that he then transferred a £28.8m slice of this money to a secret offshore trust for Mone and her children. The affair stinks of “moral corruption”, said The Guardian. “If capitalism during a national emergency can be so easily rigged to favour connected insiders, then the country is in trouble.”
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
I’ve always believed that the PPE procurement “farce” was more cock-up than conspiracy, said Hugo Rifkind in The Times. Though it never looked good that contracts were dished out to Tory donors and Matt Hancock’s pub landlord, I put it down to “the powers that be” making poor decisions because they were in a panic – as the rest of us were, and “all we had to procure was toilet paper”. But the theory “doesn’t half take a battering when confronted with a Tory peer and her kids being £29m richer than they were in 2019”. That’s something new – and at a time when public faith in government is already low, it will do “colossal damage”.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Fed leaves rates unchanged as Powell warns on tariffs
speed read The Federal Reserve says the risks of higher inflation and unemployment are increasing under Trump's tariffs
-
'The program long ago ceased to be temporary help'
Instant Opinion Opinion, comment and editorials of the day
-
Denmark to grill US envoy on Greenland spying report
speed read The Trump administration ramped up spying on Greenland, says reporting by The Wall Street Journal
-
Mental health: a case of overdiagnosis?
Talking Point Issues at 'the milder end of the spectrum' may be getting wrongly pathologised
-
Fighting against fluoride
Feature A growing number of communities are ending water fluoridation. Will public health suffer?
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
-
Bird flu: The viral threat pushing up egg prices
Feature
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
-
New Alzheimer's drug rejected: is Nice being nasty?
Talking Point Health watchdog has announced lecanemab will be denied to NHS patients on cost grounds